Genmab — November 2022
-
Genmab/Jyske: Sænker til "hold" efter stærk comeback https://www.proinvestor.com/investornyt/909196/genmab-jyske-saenker-til-hold-efter-staerk-comeback
-
"Sjovt" som et medie vælger overskriften hold, når de har muligheden for enten at skrive hæver kursmålet fra 2850 til 3400 eller at anbefalingen ændres fra fra køb til hold. Altså alt i alt er det en positiv analyse. Kursmålet er med potentiale for yderligere stigning. Altså indtil de øger målet igen.
-
slightly better title
: "Bank believes in cancer approval for Genmab" - https://medwatch.com/News/Pharma___Biotech/article14634043.ece -
or the original danish https://medwatch.dk/article14633990.ece
-
-
Olie, USD, inflation og renter kommer ned de næste 12 mdr !
-
Ny ATH, nice
-
yeehaw!
-
GEN1042 nyheder på torsdag???
-
-
After FDA Rejection, Spectrum Shelves Development On Poziotinib https://finance.yahoo.com/news/fda-rejection-spectrum-shelves-development-145947732.html ; potential amivantamab competitor, even though ami was deemed superior already https://www.clinicaltrialsarena.com/comment/janssens-amivantamab-has-competitive-edge-over-spectrums-and-takedas-exon-20-mutation-directed-tkis-in-nsclc/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind